Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 84 pages report, published by Global Markets Direct

Keywords : Deep Vein Thrombosis (DVT) Therapeutic Products under Development, Key Players in Deep Vein Thrombosis (DVT) Therapeutics, Deep Vein Thrombosis (DVT) Pipeline Overview, Deep Vein Thrombosis (DVT) Pipeline, Deep Vein Thrombosis (DVT) Pipeline Assessment

Report ThumbnailSeptember-2013
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT). Deep Vein Thrombosis (DVT) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Deep Vein Thrombosis (DVT).
- A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2013 8
  • Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 12
  • Late Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 29
  • Assessment by Route of Administration, H2 2013 30
  • Assessment by Stage and Route of Administration, H2 2013 31
  • Assessment by Molecule Type, H2 2013 32
  • Assessment by Stage and Molecule Type, H2 2013 33
  • List of Tables
  • Number of Products Under Development for Deep Vein Thrombosis (DVT), H2 2013 8
  • Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Number of Products under Investigation by Universities/Institutes, H2 2013 12
  • Comparative Analysis by Late Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • Bristol-Myers Squibb Company, H2 2013 18
  • Boehringer Ingelheim GmbH, H2 2013 19
  • Generex Biotechnology Corporation, H2 2013 20
  • BioLineRx, Ltd., H2 2013 21
  • Bayer AG, H2 2013 22
  • Alchemia Limited, H2 2013 23
  • Emisphere Technologies, Inc., H2 2013 24
  • Merrion Pharmaceuticals Plc, H2 2013 25
  • Thrombotargets Corporation, H2 2013 26
  • Diakron Pharmaceuticals, Inc., H2 2013 27
  • Synthon BV, H2 2013 28
  • Assessment by Monotherapy Products, H2 2013 29
  • Assessment by Stage and Route of Administration, H2 2013 31
  • Assessment by Stage and Molecule Type, H2 2013 33
  • Deep Vein Thrombosis (DVT) Therapeutics - Drug Profile Updates 53
  • Deep Vein Thrombosis (DVT) Therapeutics - Discontinued Products 73
  • Deep Vein Thrombosis (DVT) Therapeutics - Dormant Products 74
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Deep Vein Thrombosis (DVT) Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Deep Vein Thrombosis (DVT) 8
  • Deep Vein Thrombosis (DVT) Therapeutics under Development by Companies 10
  • Deep Vein Thrombosis (DVT) Therapeutics under Investigation by Universities/Institutes 12
  • Late Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Deep Vein Thrombosis (DVT) Therapeutics - Products under Development by Companies 16
  • Deep Vein Thrombosis (DVT) Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Deep Vein Thrombosis (DVT) Therapeutics Development 18
  • Bristol-Myers Squibb Company 18
  • Boehringer Ingelheim GmbH 19
  • Generex Biotechnology Corporation 20
  • BioLineRx, Ltd. 21
  • Bayer AG 22
  • Alchemia Limited 23
  • Emisphere Technologies, Inc. 24
  • Merrion Pharmaceuticals Plc 25
  • Thrombotargets Corporation 26
  • Diakron Pharmaceuticals, Inc. 27
  • Synthon BV 28
  • Deep Vein Thrombosis (DVT) - Therapeutics Assessment 29
  • Assessment by Monotherapy Products 29
  • Assessment by Route of Administration 30
  • Assessment by Molecule Type 32
  • Drug Profiles 34
  • apixaban - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • rivaroxaban - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • tecarfarin - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • BL-5030 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • TT-105 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • dabigatran etexilate - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • BLX-155 - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • ardeparin sodium - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • DP-4088 - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • ardeparin sodium - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • fondaparinux sodium - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • Leucine Rich Repeat (In FLII) Interacting Protein-1 shRNA Lentivirus - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • fondaparinux sodium - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Deep Vein Thrombosis (DVT) Therapeutics - Drug Profile Updates 53
  • Deep Vein Thrombosis (DVT) Therapeutics - Discontinued Products 73
  • Deep Vein Thrombosis (DVT) Therapeutics - Dormant Products 74
  • Deep Vein Thrombosis (DVT) - Product Development Milestones 75
  • Featured News & Press Releases 75
  • Sep 01, 2013: Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data 75
  • Sep 01, 2013: Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence 75
  • Aug 28, 2013: FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism 76
  • Jul 11, 2013: FDA Accepts Eliquis Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery 77
  • Jun 26, 2013: Bayer's Xarelto Receives Positive Recommendation From NICE As New Treatment Option For Pulmonary Embolism And Deep Vein Thrombosis 77
  • Jun 24, 2013: Boehringer Ingelheim Submits Application To EMA For Use Of Pradaxa In Treatment Of Deep Vein Thrombosis And Pulmonary Embolism 78
  • Jun 24, 2013: Bayer To Present New Data On Clinical Benefit Of Xarelto At ISTH 2013 78
  • May 27, 2013: ThromboGenics's Partner Alcon Launches Jetrea In Denmark And Sweden 80
  • Apr 19, 2013: Bayer's Rivaroxaban Obtains NICE Recommendation For Treatment Of Pulmonary Embolism And Deep Vein Thrombosis 80
  • Mar 01, 2013: Bayer Announces Presentation Of New Data From Clinical Development Program Supporting Oral Anticoagulant Rivaroxaban At 62nd ACC Annual Scientific Session And Exposition 81
  • Appendix 83
  • Methodology 83
  • Coverage 83
  • Secondary Research 83
  • Primary Research 83
  • Expert Panel Validation 83
  • Contact Us 84
  • Disclaimer 84

Please select a license type

Share

Related Products

Global Markets DirectDeep Vein Thrombosis (DVT) - Pipeline Review, H2 2013Product ThumbnailDeep Vein Thrombosis (DVT) - Pipeline Review, H2 2013, Industry ReportProduct #: 113324
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved